PRINT24.COM
15.6.2016 10:05:08 CEST | Business Wire | Press release
The online printer UNITEDPRINT SE – to which one of its most well-known brands, print24.com, belongs – is extending its product range to include Thread-stitched Books and ultralight Flyers, and will also be offering posters in single quantities in A0 and A1 formats. In addition, the already attractive prices for Folded flyers in quantities of 50,000 und Brochures with Perfect binding starting from 2,500 pieces will be reduced by a further 10%.
Ali Jason Bazooband, Managing Director for Innovation/Marketing of UNITEDPRINT SE, says:
“We receive daily requests from customers for new products and services, and we strive to offer these as quickly and cost-effectively as possible. I’m therefore very excited to be able to now also offer our customers Books with Thread-stitching, which in comparison to our Books with Perfect binding, are up to 50% less expensive. Furthermore, we have supplemented our product range to include ultralight Flyers of 70 gsm and 90 gsm and Posters in single quantities in A0 and A1 formats. We have also been able to reduce the price of our Top sellers by 10%, such as the 135 gsm Folded flyers in A4 and A5 formats starting from 50,000 pieces, and A4 and A5 Brochures with Perfect binding in quantities from 2,500.”
In comparison to Books with Perfect binding, Books with Thread-stitching are clearly more durable and of higher quality. They can be ordered from print24.com in single quantities or more. With their extremely low weight of 70 gsm or 90 gsm, the ultralight Flyers are ideal for reducing postage costs and perfect as advertising inserts. Posters in single quantities in A0 and A1 formats are in high demand for use as advertising support such as customer stoppers and displays.
print24.com is a UNITEDPRINT SE brand, a global and innovation-oriented e-commerce company for print and media. As one of Europe’s leading online printers, UNITEDPRINT SE is represented in the marketplace by the renowned brands print24, Easyprint, Unitedprint, getprint, printwhat, FIRSTPRINT, DDK PRINT BIG, infowerk, and Unitedprint Shop Services (USS). The company employs a staff of over 700 people at 26 locations worldwide (in Germany, 21 other European countries, and in Brazil, China, Canada, and the US). In addition to the standard print products, the company provides its customers with high-quality products ranging from the textile printing, photo printing, advertising equipment printing and gastronomy sectors. Customers can also benefit from their 24-hour availability as well as their 30/60/90-payment model, which is unique in this sector.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160615005490/en/
Contact:
unitedprint.com SE
Maria Lehmann
0049 (0)351 / 27225388
presse@unitedprint.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom